Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners
Por:
Chazan, G, Jupp, J, Bauters, T, Duncan, N, Weddle, KJ, Nomura, H, O'Connor, S, Chan, A, Alkhudair, N, Alsamrani, M, Buie, LW, Chambers, P, Chieh, TW, DeRemer, DL, Duvivier, F, Katabalo, D, McFarlane, T, Mckavanagh, D, Mensah, K, Martinez, EM, Rowan, G, Sae-teaw, M, Tadesse, TA, Weru, I, Alexander, M
Publicada:
1 dic 2022
Ahead of Print:
1 oct 2021
Resumen:
Introduction The coronavirus of 2019 pandemic has necessitated vast and rapid changes in the way oncology pharmacy services are delivered around the world. Methods/aims An international survey of oncology pharmacists and technicians was conducted via the International Society of Oncology Pharmacy Practitioners and collaborating global pharmacy organisations to determine the impact that the coronavirus of 2019 has had on pharmacy service delivery, pharmacy practitioners and oncology practice. Results The survey received 862 responses from 40 different countries from September to October 2020. The majority of respondents were pharmacists (n = 841, 97.6%), with 24% involved in the direct care of patients with the coronavirus of 2019. Of the survey participants, 55% increased their time working remotely, with remote activities including dispensing, patient assessment/follow-up and attending multi-disciplinary rounds. Respondents reported a 72% increase in the use of technology to perform remote patient interaction activities and that participation in educational meetings and quality improvement projects was reduced by 68% and 44%, respectively. Workforce impacts included altered working hours (50%), cancelled leave (48%) and forced leave/furloughing (30%). During the pandemic, respondents reported reduced access to intensive care (19%) and anti-cancer (15%) medications. In addition, 39% of respondents reported reduced access to personal protective equipment, including N95 masks for chemotherapy compounding. Almost half of respondents (49%) reported that cancer treatments were delayed or intervals were altered for patients being treated with curative intent. A third of practitioners (30%) believed that patient outcomes would be adversely impacted by changes to pharmacy services. Sixty-five percent of respondents reported impacts on their mental health, with 12% utilising support services. Conclusion The coronavirus of 2019 pandemic has altered the way oncology pharmacy services are delivered. These results demonstrate the adaptability of the oncology pharmacy profession and highlight the importance of formal evaluation of the varied practice models to determine the evidence-based practices that enhance pharmacy services and, thus, should be reinstated as soon as practical and reasonable.
Filiaciones:
Chazan, G:
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
Jupp, J:
Alberta Hlth Serv, Pharm Serv, Edmonton, AB, Canada
Bauters, T:
Ghent Univ Hosp, Pharm Dept, Ghent, Belgium
Duncan, N:
Queen Elizabeth Hosp, Pharm Dept, Birmingham, W Midlands, England
Weddle, KJ:
Purdue Univ, Coll Pharm, W Lafayette, IN 47907 USA
Nomura, H:
Natl Canc Ctr Hosp East, Dept Data Sci Pharm, Kashiwa, Chiba, Japan
O'Connor, S:
St Vincents Hosp, Pharm Dept, Fitzroy, Vic, Australia
Dept Hlth Victoria, Commissioning & Syst Improvement Div, Melbourne, Vic, Australia
Chan, A:
Univ Calif Irvine, Dept Clin Pharm Practice, Irvine, CA USA
Alkhudair, N:
King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
Alsamrani, M:
Minist Natl Guard Hlth Affairs, Pharmaceut Care Serv, Riyadh, Saudi Arabia
Buie, LW:
Mem Sloan Kettering Canc Ctr, Dept Pharm, New York, NY USA
Chambers, P:
Univ Coll London Hosp NHS Trust, London, England
UCL, Sch Pharm, London, England
Chieh, TW:
Univ Malaya, Med Ctr, Pharm Dept, Kuala Lumpur, Malaysia
DeRemer, DL:
Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32611 USA
Duvivier, F:
CHR Verviers, Pharm Dept, Verviers, Belgium
Katabalo, D:
Bugando Med Ctr, Mwanza, Tanzania
Catholic Univ Hlth & Allied Sci, Sch Pharm, Dept Pharm Practice & Therapeut, Mwanza, Tanzania
McFarlane, T:
Univ Waterloo, Waterloo, ON, Canada
Mckavanagh, D:
Queensland Hlth, Clin Excellence Queensland, 0Ffice Chief Clin Informat Officer, Brisbane, Qld, Australia
Mensah, K:
Kwame Nkrumah Univ Sci & Technol, Coll Hlth Sci, Fac Pharm & Pharmaceut Sci, Kumasi, Ghana
Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, Durban, South Africa
Kwame Nkrumah Univ Sci & Technol, Fac Pharm & Pharmaceut Sci, Pharm Practice Dept, Kumasi, Ghana
Martinez, EM:
Hosp Santa Creu & Sant Pau, Pharm Serv, Barcelona, Spain
Rowan, G:
Peter MacCallum Canc Ctr, Pharm Dept, 305 Grattan St, Melbourne, Vic 3011, Australia
Sae-teaw, M:
Ubon Ratchathani Univ, Fac Pharmaceut Sci, Ubon Ratchathani, Thailand
Tadesse, TA:
Addis Ababa Univ, Coll Hlth Sci, Sch Pharm, Addis Ababa, Ethiopia
Weru, I:
Kenyatta Natl Hosp, Pharm Div, Nairobi, Kenya
Alexander, M:
Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
Peter MacCallum Canc Ctr, Pharm Dept, 305 Grattan St, Melbourne, Vic 3011, Australia
|